



2nd Annual

HEART iN DIABETES

Where the Heart, Kidney and Diabetes Meet in Clinical Practice


July 13–15, 2018

Loews Philadelphia Hotel



www.HEARTiNDIABETES.com

Jointly Provided By:



Administered By:



Dear Friends & Colleagues,

We are pleased to invite you to the 2nd Annual Heart in Diabetes (HiD) Medical Conference. Following the incredible success, amazing evaluations of the inaugural HiD, extensive positive feedback and expressed desire for another such meeting, the 2nd HiD will take place July 13-15, 2018, at the Loews Philadelphia Hotel.

This CME program is a unique medical conference designed to evaluate the state-of-the-art clinical research of heart disease in diabetes and its implications on practice. HiD will bring together world-renowned clinical leaders in Diabetes and Cardiovascular Disease, while aligning cardiologists, endocrinologists, lipidologists, nephrologists and hepatologists in developing a multi-disciplinary, comprehensive understanding of today's clinical science on the management of high-risk patients.

Recent trials have demonstrated a cardiovascular benefit from anti-hyperglycemic, lipids, HTN and inflammation agents in people with diabetes. However, among practicing professionals, including experts in the field, there is a gap in understanding the implications of these new developments and their impact in managing these patients.

The meeting provides a platform to address the clinical science of the Heart in Diabetes by providing current information and research, while highlighting impact on practice and evaluating it from the cardiology, endocrine/diabetes, kidney and Liver points of view. Topics will include: Lipids, Glucose, ACS, CHF, Atherosclerosis, Vascular, Coagulation, Arrhythmia, fatty Liver, the Kidney, and other related conditions. The meeting will promote discussion and interaction among the various specialists in how they develop their respective approaches to the management and prevention of Heart Disease in Diabetes.

If you are a Cardiologist, Endocrinologist, Nephrologist, Dialyologist, Lipidologist Internist, or simply a clinician with an interest in the Heart in Diabetes- this meeting is for you! We personally invite you to join us in this exciting endeavor.

Please register today! Do not hesitate to contact us with any questions.

We look forward to having you join us for this exciting conference in Philadelphia in July.



Yehuda Handelsman, MD, FACP, FNLA, MACE



Mikhail N. Kosiborod, MD, FACC, FAHA

Heart in Diabetes (HiD) Scientific Committee

Yehuda Handelsman, MD *Chair*
Tarzana, California

Mikhail N. Kosiborod, MD *Chair*
Kansas City, Missouri

Deepak L. Bhatt, MD
Boston, Massachusetts

Zachary T. Bloomgarden, MD
New York, New York

Matt J. Budoff, MD
Los Angeles, California

Javed Butler, MD
Atlanta, Georgia

David Cherney, PhD, MD
Toronto, Canada

Robert J. Chilton, DO
San Antonio, Texas

Michael H. Davidson, MD
Chicago, Illinois

Ralph A. DeFronzo, MD
San Antonio, Texas

Daniel Einhorn, MD
San Diego, California

Michael E. Farkouh, MD
Toronto, Canada

Sergio Fazio, MD, PhD
Portland, Oregon

Vivian A. Fonseca, MD
New Orleans, Louisiana

Alan M. Garber, MD, PHD
Houston, Texas

Peter J. Grant, MD
Leeds, United Kingdom

George Grunberger, MD
Bloomfield Hills, Michigan

Mansoor Husain, MD
Toronto, Canada

Silvio E. Inzucchi, MD
New Haven, Connecticut

Lawrence A. Leiter, MDCM
Toronto, Canada

Norman E. Lepor, MD
Los Angeles, California

Derek LeRoith, MD, PhD
New York, New York

Christos S. Mantzoros, MD
Boston, Massachusetts

Nikolaus Marx, MD
Aachen, Germany

Darren McGuire, MD
Dallas, Texas

Kausik Ray, PhD
London, United Kingdom

Benjamin M. Scirica, MD
Boston, Massachusetts

Matthew R. Weir, MD
Maryland, Baltimore



PROGRAM DESCRIPTION:

This CME conference is a unique medical meeting that brings together world-renowned clinical leaders in diabetes and cardiovascular disease with practicing clinicians with the goal of improving care of patients at high risk of cardiovascular, metabolic, and kidney diseases. At HiD, experts and clinicians explore the state-of-the-art in the clinical science of the Heart in Diabetes, with in-depth examinations of the latest clinical evidence from studies of lipid disorders, glucose abnormalities, acute coronary syndrome, congestive heart failure, atherosclerosis, vascular disease conditions, kidney disease, coagulation abnormalities, arrhythmia, and related conditions.

PROGRAM OBJECTIVES: Upon completion of this meeting, participants should be able to:

- Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia
- Evaluate the relationship between diabetes, the heart and the kidney
- Understand cardiometabolic syndrome
- Provide comprehensive management of cardiovascular conditions
- Describe the relationship between diabetes, obesity, and congestive heart failure
- Implement best practices for the management of CHF
- Describe the combined effect of lowering blood pressure and glucose on morbidity and mortality in diabetes
- Evaluate the evidence supporting the use of SGLT2 inhibitors and GLP1 RAs to reduce cardiovascular mortality in patients with T2D
- Discuss the role of incretins in the management of obesity, diabetes, and their complications
- Discuss the role of SGLT2 inhibitors in the management of obesity, diabetes, and their complications
- Describe the pathophysiologic changes leading to abnormal glucose tolerance and its role in the development of microvascular and macrovascular disease
- Recognize the role of the liver, fatty liver disease, and NASH in the development of CVD in diabetes
- Explain the role of lipids, in particular LDL-C and non-HDL-C, in the development of atherosclerosis
- Evaluate the extent of vascular disease — focus on PAD in diabetes
- Describe changes in the epidemiology of cardiovascular disease and discuss the possible impacts of changes in management recommendations have had on patient outcomes
- Identify gaps in current lipid treatment guidelines from different lipid-management organizations and describe how recommendations can be adapted to fit individual patients' needs
- Determine appropriate targets of lipid-lowering therapy, including specific LDL-C goals for individual patients
- Describe the role of PCSK9 in lipid elevations and its potential contributions to cardiovascular disease
- Appropriately diagnose and treat hypercoagulation and thrombosis as consequences of insulin resistance, inflammation, and diabetes
- Evaluate the proper administration of anti-platelet and anti-coagulation agents in the management of the high-risk patient

TARGET AUDIENCE

Cardiologists, endocrinologists, nephrologists, diabetologists, lipidologists, internists, family clinicians, and other professionals who are interested in the Heart in Diabetes.

HEART IN DIABETES PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair · Mikhail N. Kosiborod, MD, Chair · Zachary T. Bloomgarden, MD · Matthew J. Budoff, MD
Javed Butler, MD, MPH, MBA · David Cherney, CM, PhD, MD · Robert J. Chilton, DO · Michael H. Davidson, MD · Ralph A. DeFronzo, MD
Daniel Einhorn, MD · Michael E. Farkouh, MD · Sergio Fazio, MD, PhD · Vivian A. Fonseca, MD · Alan Garber, MD, PhD
Peter J. Grant, MD · George Grunberger, MD · Silvio E. Inzucchi, MD · Lawrence A. Leiter, MD · Norman E. Lepor, MD
Christos Mantzoros, MD, DSc · Nikolaus Marx, MD · Darren McGuire, MD · Richard E. Pratley, MD · Benjamin M. Scirica, MD
Matthew R. Weir, MD · Renee S. Asp, BS

The HiD Scientific Committee Gratefully Acknowledges the Unrestricted Educational Grants of
Leader Educators: **ASTRAZENECA • BI/LILLY • MERCK**
Major Educators: **AMARIN • NOVO NORDISK**

PROGRAM 2018

FRIDAY JULY 13, 2018

12:00pm – 3:00pm **Pre-Registration** Regency Ballroom Foyer 2nd Fl. Mezzanine Level

2:00PM – 2:45PM **WELCOME EXHIBITORS RECEPTION AT EXHIBIT HALL**

2:45pm – 2:55pm Welcome & Introduction
2:55pm – 3:00pm Pre-CME Questions

Yehuda Handelsman, MD · Mikhail N. Kosiborod, MD

SESSION 1 **THE HEART IN DIABETES WITH CIRCULATION**
Chair: Darren McGuire, MD

3:00pm – 3:10pm	Introduction	Darren McGuire, MD
3:10pm – 3:25pm	Glucose-Lowering Therapies & CHF in T2DM: Mechanistic Links, Clinical Data & Future Directions	Javed Butler, MD
3:25pm – 3:40pm	GLP-1 RAs for Cardiovascular Disease: Why and How	Ildiko Lingvay, MD
3:40pm – 3:55pm	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients with a Recent Coronary Event & T2DM	Eldrin F. Lewis, MD
3:55pm – 4:10pm	Secondary Prevention of CVD in Patients with T2DM: International Insights from the TECOS Trial	Ann Marie Navar, MD, PhD
4:10pm – 4:25pm	Heart Failure with Preserved Ejection Fraction: Focus on Diabetes	Sanjiv J. Shah, MD
4:25pm – 4:30pm	Wrap-up/Ask the Editor	Darren McGuire, MD

4:30PM – 5:00PM **REFRESHMENT BREAK AT EXHIBIT HALL**

SESSION 2 **PRESENTATION OF CVD IN DM**
Chairs: Peter J. Grant, MD · Silvio E. Inzucchi, MD

5:00pm – 5:25pm	Epidemiology of CVD, CHF and Mortality Risks in DM	Naveed Sattar, MD
5:25pm – 5:50pm	Gestational Diabetes & CVD	Rhonda Bentley-Lewis, MD
5:50pm – 6:15pm	Fatty Liver Disease in CVD & DM	Arun J. Sanyal, MD

SESSION 3 **IMPACT OF INFLAMMATION & TECHNOLOGY ON CVD IN DM**
Chairs: Matthew R. Weir, MD · Zachary T. Bloomgarden, MD

6:15pm – 6:40pm	The Role of Inflammation in Cardiometabolic Conditions: CANTOS - Diabetes Group	Paul M. Ridker, MD
6:40pm – 7:00pm	Clinical Impact of Technology on Prevention & Management of Heart Disease in DM	George Grunberger, MD
7:00pm – 7:15pm	Panel Discussion/Post-CME Questions	

7:15PM – 8:15PM **PRODUCT THEATER** **Non-CME** **RECEPTION SESSION** **Refreshments will be served**
Advancements in the Management of Patients with Type 2 Diabetes: Results from a Large Cardiovascular Outcomes Trial.
Supported by: **Novo Nordisk**

Michael H. Davidson, MD



SATURDAY JULY 14, 2018

5:45AM – 7:45AM **BREAKFAST SYMPOSIUM** **CME**
PCSK9 INHIBITORS IN PATIENTS WITH DIABETES: A CLOSER LOOK AT CV RISK REDUCTION



5:45am	Registration and Breakfast	
6:15am	Introduction and Pretest	Yehuda Handelsman, MD
6:25am	Understanding Diabetic Dyslipidemia – Impact for Patients	Deepak L. Bhatt, MD
6:45am	A Deep Dive into New Guidelines and Recent CV Outcomes Trials	Christie M. Ballantyne, MD
7:10am	Clinical Cases	Moderated by: Yehuda Handelsman, MD
7:30am	Posttest and Question & Answer	

Supported by an educational grant from **Amgen** | Provided by **Vindico Medical Education**

SESSION 4 **CVOT IMPACT ON CLINICAL PRACTICE GUIDELINES**
Chairs: Yehuda Handelsman, MD · Mikhail N. Kosiborod, MD

8:00am – 8:05am	Pre-CME Questions	
8:05am – 8:25am	Principles of White Paper Development in DM: Guidelines, Consensus, Statements & Algorithms	Jeffrey I. Mechanick, MD
8:25am – 8:55am	Mitigating CV Risk with AntiDM & Antilipids Drugs: Evaluating the Evidence	Sanjay Kaul, MD
8:55am – 9:15am	The Role of Guidelines on Influencing Clinical Practice: Europe Perspective- Potential Impact of CVOT	Peter J. Grant, MD
9:15am – 9:35am	ADA Recommendations for Pharmacological Management of DM & CVD	Jane E.B. Reusch, MD
9:35am – 9:55am	AACE Management Recommendations for the High-Risk CV Patient with DM	Alan Garber, MD, PhD
9:55AM – 10:25AM	REFRESHMENT BREAK AT EXHIBIT HALL	
10:25am – 11:05am	HTN in DM & CVD: Goals & Guidelines - The Great Debate	
10:25am	Higher Goals	George L. Bakris, MD
10:45am	Lower Goals	Paul K. Whelton, MD
11:05am – 11:25am	DM Canada Management Recommendations for the High-Risk CV Patient with DM	Robyn L. Houlden, MD
11:25am – 11:45am	ACC/AHA Lipids Management Recommendations for the High-Risk Patient with DM	Christie M. Ballantyne, MD
11:45am – 12:20pm	Panel Discussion	

12:30PM – 1:20PM **PRODUCT THEATER** **Non-CME** **Lunch will be provided**
Severe Hypertriglyceridemia & Pancreatitis: Including Familial Chylomicronemia Syndrome (FCS) In Your Differential Diagnosis.
Supported by: **Akcea Therapeutics**

Richard L. Dunbar, MD



SESSION 5 **MANAGEMENT OF HEART DISEASE IN DIABETES**
Chairs: Michael E. Farkouh, MD · Vivian Fonseca, MD

1:30pm – 1:55pm	The Role of Lifestyle Modification in the Prevention & Management of Cardiometabolic Risk: Clinical Recommendations & Underlying Mechanisms	Christos S. Mantzoros, MD
-----------------	---	---------------------------

SATURDAY JULY 14, 2018 (cont.)

1:55PM – 2:30PM

AWARD PRESENTATION: "Luminary in Cardiometabolic Medicine"

Key Note: Insights from a Cardiologist's Career Perspective on CVD and DM.

Richard W. Nesto, MD



2:30pm – 2:55pm

Surgical Versus Percutaneous Coronary Revascularization in Patients with DM & ACS

Michael E. Farkouh, MD

SESSION 6

THE KIDNEY IN DIABETES

Chairs: Alan Garber, MD, PhD · Ralph A. DeFronzo, MD

2:55pm – 3:15pm

Predicting, Preventing & Managing CKD & CVD Progression in People with T2DM: How to Improve Upon Traditional Approaches

Matthew R. Weir, MD

3:15pm – 3:40pm

Renal Effects of Antihyperglycemic Agents

Mark E. Cooper, MD, PhD

3:40pm – 3:50pm

Panel Discussion

3:50PM – 4:20PM

REFRESHMENT BREAK AT EXHIBIT HALL

SESSION 7

IMPACT OF DIABETES MANAGEMENT ON THE HEART

Chairs: Daniel Einhorn, MD · Norman E. Lepor, MD

4:20pm – 4:45pm

Does Anti-Hyperglycemic Combination Therapy Improve CVO in People with Diabetes & Established CVD

Ralph A. DeFronzo, MD

4:45pm – 5:15pm

Metformin is Still the Best Initial Therapy for T2DM with CVD

4:45pm

Yes

Silvio E. Inzucchi, MD

5:00pm

No

Vivian Fonseca, MD

5:15pm – 5:30pm

Role of Pioglitazone in the Prevention & Management of DM & CVD

Robert J. Chilton, DO

5:30pm – 6:00pm

Should SGLT2i or GLP-1ra be the Preferred First Choice Following Metformin?

5:30pm

SGLT2i

Zachary T. Bloomgarden, MD

5:45pm

GLP-1ra

Richard E. Pratley, MD

6:00pm – 6:20pm

The Cardiologist Approach to Managing Hyperglycemia of Diabetes

Sandeep R. Das, MD

6:20pm – 6:35pm

Panel Discussion/Post-CME Questions

6:35PM – 7:30PM

WELCOME RECEPTION AT EXHIBIT HALL

7:30PM – 9:30PM

DINNER SYMPOSIUM

CME

Food provided by **MEEF**

MEDICATIONS' CLASS EFFECTS IN DM & CVD - ALL YOU NEED TO KNOW - AND NEVER ASKED.



7:30pm

Introduction & CME Questions

Yehuda Handelsman, MD

7:50pm

The Meaning of Medications' Class Effect- Prevalence, Principles And Requirements

George L. Bakris, MD

8:10pm

Efficacy & Safety of SGLT2i- Is It A Class Effect

James R. Gavin III, MD, PhD

8:30pm

Distinguishing Among GLP1-RAs: Are There Any Class Effects?

Mikhail N. Kosiborod, MD

8:50pm

Panel Discussion and Q&A: How Do We Choose Between and Within Classes to Meet Individual Patient Needs?

Panel: **George L. Bakris, MD • James R. Gavin III, MD, PhD • Mikhail N. Kosiborod, MD**

Sanjay Kaul, MD • Richard E. Pratley, MD • Matthew R. Weir, MD

Moderator: Yehuda Handelsman, MD

9:20–9:30pm

Concluding Remarks

Supported by an Educational Grant from: **AstraZeneca**

SUNDAY JULY 15, 2018

7:00AM – 8:00AM

REGISTRATION • CONTINENTAL BREAKFAST

SESSION 8

VASCULAR DISEASE & THROMBOSIS

Chairs: Christos S. Mantzoros, MD · Sergio Fazio, MD, PhD

7:50am – 8:00am

Pre-CME Questions

8:00am – 8:20am

Peripheral Vascular Disease in DM

Joshua Beckman, MD

8:20am – 8:40am

Anti-thrombotic Therapy in Diabetes

Deepak L. Bhatt, MD

8:40am – 8:55am

Panel Discussion

SESSION 9

CHF & DIABETES

Chairs: Michael H. Davidson, MD · Robert J. Chilton, DO

8:55am – 9:15am

Epidemiology and Causes of Heart Failure in Diabetes

Biykem Bozkurt, MD, PhD

9:15am – 9:35am

CHF Outcome Post CABG in Diabetes

Mark Kearney, MD

9:35am – 9:55am

Management of CHF in Diabetes

Mikhail N. Kosiborod, MD

9:55am – 10:10am

Panel Discussion

10:10AM – 10:30AM REFRESHMENT BREAK

SESSION 10

IMPACT OF DIABETES & DYSLIPIDEMIA ON CVD

Chairs: Deepak L. Bhatt, MD · George Grunberger, MD

10:30am – 11:10am

Point-Counter-Point: Do LDL-C Levels Predict Diabetes?

10:30am

Yes

Michael H. Davidson, MD

10:50am

No

Sergio Fazio, MD, PhD

11:10am – 11:30am

Atherosclerosis of Diabetes: Development and Prevention

Jorge Plutzky, MD

11:30am – 11:50pm

Lipids Cardiovascular Outcome Trials: Focus on the Diabetes Cohort

Norman E. Lepor, MD

11:50pm – 12:10pm

The Role of Dyslipidemia - Beyond LDL - in the Development of CVD in Diabetes

Michael Miller, MD

12:10pm – 12:45pm

Panel Discussion/Post-CME Questions

12:45PM

ADJOURN

FACULTY 2018



Yehuda Handelsman, MD
FACP, FNLA, MACE
 Chair & Program Director
 Med. Director & Principal
 Investigator
 Metabolic Institute of America
 Chair & Founder, ICIR
 Chair & Founder, ILF
 Tarzana, California



Mikhail N. Kosiborod, MD
FACC, FAHA
 Professor of Medicine
 Saint Luke's Mid America Heart
 Institute
 University of Missouri-Kansas City,
 Kansas City, Missouri



**George L. Bakris, MD, Hon.
 DSc, FASN, FASH, FAHA**
 Professor of Medicine
 Director, ASH Comprehensive
 Hypertension Center
 University of Chicago Medicine
 Principal Investigator, FIDELIO Trial
 Chicago, Illinois



Christie M. Ballantyne, MD
 Professor of Medicine
 Vice Chair of Research for the
 Department of Medicine
 Chief, Section of Cardiovascular
 Research
 Chief, Section of Cardiology
 Department of Medicine, Baylor
 College of Medicine
 Houston, Texas



Joshua Beckman, MD, MS
 Professor of Medicine
 Director, Vascular Medicine
 Section
 Vanderbilt Translational and
 Clinical Cardiovascular Research
 Center
 Vanderbilt University Medical
 Nashville, Tennessee



Rhonda Bentley-Lewis, MD
MBA, MMSc
 Assistant Professor of Medicine
 Harvard Medical School
 Massachusetts General Hospital
 Medicine/Diabetes
 Boston, Massachusetts



Deepak L. Bhatt, MD, MPH
FACC, FAHA, FSCAI, FESC
 Executive Director
 Interventional CVD Programs
 Brigham and Women's Hospital
 Heart & Vascular Center
 Professor of Medicine, Harvard
 Medical School
 Boston, Massachusetts



Zachary T. Bloomgarden
MD, MACE
 Clinical Professor
 Department of Medicine
 Icahn School of Medicine at
 Mount Sinai
 Editor, the Journal of Diabetes
 New York, New York



Biykem Bozkurt, MD, PhD
FACC, FAHA, FHFS, FACP
 Professor of Medicine,
 The Mary and Gordon Cain Chair
 W.A. "Tex" and Deborah
 Mancief, Jr., Chair
 Medicine Chief and Medical Care
 Line Executive, DeBakey VA
 Medical Center
 Director, Winters Center for Heart
 Failure Research,
 Associate Director, Cardiovascular
 Research Institute
 Baylor College of Medicine
 Houston, Texas



Javed Butler, MD, MPH, MBA
 Professor and Chairman
 Department of Medicine
 University of Mississippi
 Oxford, Mississippi



Robert J. Chilton, DO, FACC
 Professor of Medicine
 Department of Medicine
 Division of Cardiology
 The University of Texas
 Health Science Center
 San Antonio, Texas



**Mark E. Cooper, AO, MBBS
 PhD, FRACP, FAHMS**
 Head of the Department of
 Diabetes
 Central Clinical School
 Monash University
 Senior Endocrinologist, Alfred
 Health Clinic
 Melbourne, Australia



**Sandeep R. Das, MD, MPH
 MBA, FACC, FAHA**
 Associate Professor of Internal
 Medicine, Cardiology Division
 University of Texas Southwestern
 Medical Center
 Parkland Center for Healthcare
 Innovation and Clinical Outcomes
 Medical Director for Acute
 Coronary Care, Parkland Hospital
 Dallas, Texas



Michael H. Davidson, MD
FACC, FACP, FNLA
 Professor, Director of the Lipid
 Clinic
 The University of Chicago Pritzker
 School of Medicine
 Chicago, Illinois



Ralph A. DeFronzo, MD
BMS, MS, BS
 Professor of Medicine
 Chief, Diabetes Division
 University of Texas Health Science
 Center at San Antonio (UTHSCSA)
 Deputy Director,
 Texas Diabetes Institute
 San Antonio, Texas



Daniel Einhorn, MD
FACP, FACE
 President, Diabetes and Endocrine
 Associates
 Medical Director, Scripps Whittier
 Diabetes Institute
 Clinical Professor of Medicine
 University of California, San Diego
 Past President, AACE
 Past President, ACE
 Trustee, ACE
 La Jolla, California



Michael E. Farkouh, MD
FRCP, MSc, FACC, FAHA
 Peter Munk Cardiac Centre
 University Health Network
 Peter Munk Chair in Multinational
 Clinical Trials
 Toronto, Ontario, Canada



Sergio Fazio, MD, PhD
 The William and Sonja Connor
 Chair of Preventive Cardiology
 Professor of Medicine and
 Physiology & Pharmacology
 Director, Center for Preventive
 Cardiology
 Knight Cardiovascular Institute
 Oregon Health & Science
 University
 Portland, Oregon



Vivian Fonseca, MD, FRCP
 Professor of Medicine and
 Pharmacology
 Assistant Dean for Clinical
 Research
 Tullis Tulane Alumni Chair in
 Diabetes
 Chief, Section of Endocrinology
 Tulane University Health Sciences
 New Orleans, Louisiana



Alan Garber, MD, PhD
FACE, MACE
 Professor, Department of
 Medicine, Biochemistry and
 Molecular Biology, and Molecular
 and Cellular Biology
 Baylor College of Medicine
 Attending Physician, Baylor St.
 Luke's Medical Center
 Houston, Texas



Peter J. Grant, MD, FMedSci
 Professor of Medicine and
 Consultant Physician.
 University of Leeds/Leeds
 Teaching Hospitals NHS
 Trust/Leeds Institute of
 Cardiovascular and Metabolic
 Medicine, LIGHT Laboratories
 Leeds, United Kingdom



George Grunberger, MD
FACP, FACE
 Chairman, Grunberger Diabetes
 Institute
 Clinical Professor, Internal
 Medicine and Molecular Medicine
 & Genetics
 Wayne State University
 School of Medicine
 Professor, Internal Medicine
 Oakland University William
 Beaumont School of Medicine
 Visiting Professor, Internal
 Medicine
 First Faculty of Medicine, Charles
 University, Prague, Czech Republic
 Immediate Past President, AACE
 President Elect, ACE
 Bloomfield Hills, Michigan



Robyn L. Houlden, MD
FRCP
 Professor of Medicine
 Professor and Chair
 Division of Endocrinology
 Queen's University
 Kingston, ON, Canada



Silvio E. Inzucchi, MD
 Professor of Medicine
 Clinical Chief, Section of
 Endocrinology
 Director, Endocrinology &
 Metabolism Fellowship
 Yale School of Medicine
 Medical Director, Diabetes Center
 Yale-New Haven Hospital
 New Haven, Connecticut



Sanjay Kaul, MD, FACC, FAHA
 Professor of Medicine
 Division of Cardiology
 Cedars-Sinai Medical Center
 David Geffen School of Medicine
 UCLA
 Ronald Reagan UCLA Medical
 Fellow, American Heart
 Association
 Fellow, American College of
 Cardiology
 Los Angeles, California



Mark Kearney, MBChB
MRCP, MD
 British Heart Foundation Professor
 Cardiovascular & Diabetes
 Research
 Director, Leeds Institute of
 Cardiovascular & Metabolic
 Medicine
 Research Lead, Heart Failure
 Services
 Deputy Dean, School of Medicine
 University of Leeds
 Leeds, United Kingdom



Norman E. Lepor, MD, FACC
FAHA, FSCAI
 Clinical Professor of Medicine
 Geffen School of Medicine-UCLA
 Cedars-Sinai Heart Institute
 Co-director, Cardiovascular
 Imaging
 Westside Medical Imaging/
 Westside Medical Associates
 Los Angeles, California



Eldrin F. Lewis, MD, MPH
FACC, FAHA
 Director, Cardiovascular Clerkship
 Associate Professor of Medicine
 Harvard Medical School
 Associate Physician
 Brigham and Women's Hospital
 Advanced Heart Disease
 Boston, Massachusetts



Ildiko Lingvay, MD
MPH, MScS
 Professor of Medicine
 Division of Endocrinology/
 Department of Internal Medicine
 And Department of Clinical
 Sciences
 UT Southwestern Medical Center
 Dallas, Texas



Christos S. Mantzoros, MD, DSc
 Professor of Medicine
 Harvard Medical School
 Chief of Endocrinology
 Diabetes & Metabolism
 Editor-in-Chief,
 Metabolism, Clinical &
 Experimental
 Boston, Massachusetts



Darren McGuire, MD, MHSc
 Professor of Internal Medicine
 Division of Cardiology
 Dallas Heart Ball Chair for
 Research on Heart Disease in
 Women
 University of Texas Southwestern
 Deputy Editor, *Circulation*
 Dallas, Texas



Jeffrey I. Mechanick, MD
FACP, FACE, FACN, ECNU
 Professor of Medicine
 Medical Director of the Kravis
 Center for Cardiovascular Health
 Director of Metabolic Support
 Divisions of Cardiology and
 Endocrinology, Diabetes and
 Bone Disease
 Icahn School of Medicine at
 Mount Sinai
 New York, New York



Michael Miller, MD, FACC
FAHA, FNLA, FASPC
 Professor of Cardiovascular
 Medicine
 Epidemiology & Public Health
 University of Maryland
 School of Medicine
 Baltimore, Maryland



Ann Marie Navar, MD, PhD
 Assistant Professor and Director
 of Innovation
 Division of Cardiology, Department
 of Medicine
 Duke Clinical Research Institute
 Durham, North Carolina



Richard W. Nesto, MD, FAHA
FACC, FRCP (Edin.)
 Executive Vice President
 Chief Medical Officer
 Lahey Health
 Professor of Medicine
 Tufts Medicine School
 Burlington, Massachusetts



Jorge Plutzky, MD
 Associate Professor of Medicine
 Cardiovascular Division
 Director, The Vascular Disease
 Prevention Program
 Brigham and Women's Hospital
 Harvard Medical School
 Boston, Massachusetts



Richard E. Pratley, MD
 Samuel E. Crockett Chair in
 Diabetes Research
 Senior Investigator and Diabetes
 Program Lead
 Research Institute for Metabolism
 and Diabetes
 Associate Medical Director of
 Research and Education, Florida
 Hospital Diabetes Institute
 Orlando, Florida



Jane EB Reusch, MD
 Professor of Medicine
 Bioengineering and Biochemistry
 Endocrinology, Metabolism and
 Diabetes
 Associate Director, Center for
 Women's Health Research
 University of Colorado Anschutz
 Denver, Colorado



Paul M. Ridker, MD, MPH
FACC, FAHA
 Director of the Center for
 Cardiovascular Disease Prevention
 Translational Research Unit
 Brigham and Women's Hospital
 Eugene Braunwald Professor of
 Medicine
 Harvard Medical School
 Boston, Massachusetts



Arun J. Sanyal, MBBS, MD
 Professor of Medicine, Physiology and
 Molecular Pathology
 Division of Gastroenterology
 Hepatology and Nutrition
 VCU Medical Center
 Director, Education Core, CCTR
 Virginia Commonwealth University
 Richmond, Virginia



Naveed Sattar, MD, FMedSci
 Professor of Metabolic Medicine
 Institute of Cardiovascular and
 Medical Sciences
 University of Glasgow
 Glasgow, Scotland, UK



Sanjiv J. Shah, MD, FAHA
FACC, FASE
 Professor of Medicine
 Division of Cardiology
 Director, T1 Center for
 Cardiovascular Developmental
 Therapeutics
 Director, Northwestern HFpEF
 Program Northwestern University
 Feinberg School of Medicine
 Chicago, Illinois



Matthew R. Weir, MD
 Professor and Director
 Division of Nephrology
 Department of Medicine
 University of Maryland
 School of Medicine
 Baltimore, Maryland



Paul K. Whelton, MB
MD, MSc
 Clinical Professor of Medicine
 Show Chwan Professor of Global
 Public Health
 Tulane University
 School of Public Health and
 Tropical Medicine
 School of Medicine
 New Orleans, Louisiana



Register online: www.heartindiabetes.com/registration

Or email: info@tmioa.com

To register by phone: (818) 342-1889

CANCELLATION POLICY: A full refund will be given if written notice of cancellation is received by Friday, May 11, 2018. A \$75 cancellation fee will be charged for cancellation between May 12, 2018 and June 15, 2018. After June 15, 2018 there will be NO REFUND. Cancellations must be submitted via e-mail to info@tmioa.com or by phone at 818-342-1889.

ACCREDITATION INFORMATION

You can earn up to 18.75 credits

CME ACCREDITATION

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Designation Statement

The PESI Inc. designated this live activity for a maximum of 18.75 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity

International CME

International Physicians are formally eligible for *AMA PRA Category 1 Credit[™]*.

Physician Assistants

AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and *AMA PRA Category 1 Credit[™]* for the PRA from organizations accredited by ACCME.

Nurses

For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit[™] issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CA Nurses

Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 2nd HiD for approximately 18.75 contact hours.

Pharmacists

For the purpose of recertification, the American Council of Pharmacy Education accepts AMA PRA

Category 1 Credit[™] issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE

The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI, Inc. as approved ACCME provider. This course qualifies for 18.75 continuing education hours.

REGISTERED DIETICIANS

For the purpose of recertification the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit[™].

Satisfactory Completion for credits:

All attendees must have completed and turned in a course attendance/evaluation form prior to leaving the conference. Each session claimed for credit must be attended in its entirety.

ACCOMMODATIONS

The 2nd Annual Heart in Diabetes (HiD) CME conference will be held at the Loews Philadelphia Hotel at 1200 Market St, Philadelphia, PA 19107 USA (215) 627-1200 <https://www.loewshotels.com/philadelphia-hotel>. To reserve a room at the special rate of \$159 single/double a night for conference participants and their guests please go online: <https://www.heartindiabetes.com/accomodations> OR call (888) 575-6397 to make your individual reservation within the room block by providing the following information:

Event Name: 2nd Annual Congress on Heart in Diabetes (HiD)

Reservation ID: TMI12J

Group rate is available until June 16, 2018 subject to availability. Rooms will be available on a first-come basis, and will be available until all are filled. Group room rates will be available three (3) days prior to and three (3) days after the event date. If you need special accommodations, or if you have any questions about access to any of our activities, please contact the meeting organizers at 818 342 1889 or info@tmioa.com

The HiD Scientific Committee Gratefully Acknowledges the Corporate Support of

Sapphire Level: AMGEN • JANSSEN • SANOFI | Emerald Level: AKCEA • NOVO NORDISK

The Metabolic Institute of America (TMIOA)

18372 Clark Street #212, Tarzana, CA 91356



2nd Annual

HEART IN DIABETES

Where the Heart, Kidney and Diabetes Meet in Clinical Practice

NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS CA
PERMIT # 659

July 13–15, 2018 • Loews Philadelphia Hotel • 1200 Market St. Philadelphia, PA 19107

USE COUPON CODE “BROCHURE” AND SAVE 10% ON REGISTRATION

ATTENDANCE IS LIMITED!

Register online: www.heartindiabetes.com/registration

Or email us: info@tmioa.com

To register by phone: (818) 342-1889

Cancellation Policy: A full refund will be given if written notice of cancellation is received by Friday, May 11, 2018. A \$75 cancellation fee will be charged for cancellation between May 12, 2018 and June 15, 2018. After June 15, 2018 there will be NO REFUND. Cancellations must be submitted via e-mail to info@tmioa.com or by phone at 818-342-1889.

ENDORISING ORGANIZATIONS:

- American Association of Clinical Endocrinologists (AACE)
- American Society of Endocrine Physician Assistants
- The American Society for Preventive Cardiology (ASPC)
- World Obesity Organization
- FH Foundation
- Pediatric Endocrine Society
- National Lipid Association (NLA)

MEDIA PARTNERS:

- Journal of Diabetes
- Bentham Science
- Conference Locate
- Elsevier
- JSciMedCentral
- VuMedi
- Sage Publishing: Diabetes & Cardiovascular Disease Research
- Healio: Cardiology Today & Endocrine Today
- Physician's Weekly
- Diabetes in Control
- Cardiology Advisor
- Endocrine Web
- SciTechnol: International Journal of Cardiovascular Research

For additional information on
REGISTRATION • ACCOMODATION • SUPPORT • EXHIBITS
(818) 342-1889 info@tmioa.com
www.heartindiabetes.com